Pharmaceuticals company Hikal announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations: Reported at Rs 5,194 million for Q4FY26, compared to Rs 5,524 million in Q4FY25, representing a YoY decrease of 5.97%. On a QoQ basis, it increased by 5.08% from Rs 4,943 million in Q3FY26. For FY26, revenue was Rs 17,126 million, down 7.91% YoY from Rs 18,598 million in FY25. Net Profit/Loss for the period: Reported a profit of Rs 144 million for Q4FY26, compared to Rs 502 million in Q4FY25 (YoY decrease of 71.31%). For FY26, the company reported a net loss of Rs 488 million, compared to a profit of Rs 908 million in FY25. Standalone Financial Highlights: Revenue from operations: Reported at Rs 5,194 million for Q4FY26, compared to Rs 5,524 million in Q4FY25 (YoY decrease of 5.97%). On a QoQ basis, it increased by 5.08% from Rs 4,943 million in Q3FY26. For FY26, revenue stood at Rs 17,126 million, a decrease of 7.91% YoY from Rs 18,598 million in FY25. Net Profit/Loss for the period: Reported a profit of Rs 146 million for Q4FY26, compared to Rs 503 million in Q4FY25 (YoY decrease of 70.97%). For FY26, the company reported a net loss of Rs 487 million, compared to a profit of Rs 909 million in FY25. Business Highlights: Segment-wise Performance: Pharmaceuticals: Revenue for Q4FY26 stood at Rs 2,916 million, compared to Rs 3,513 million in Q4FY25. For FY26, segment revenue was Rs 10,210 million. Crop Protection: Revenue for Q4FY26 stood at Rs 2,278 million, compared to Rs 2,011 million in Q4FY25. For FY26, segment revenue was Rs 6,916 million. Dividend: The Board recommended a final dividend of Rs 0.40 per equity share for the financial year 2025-26. Combined with the interim dividend of Rs 0.20 per share paid in March 2026, the total dividend aggregates to Rs 0.60 per equity share (30%). Appointment: Mr. Sandip Parikh (DIN: 00030990) was appointed as an Additional Director in the category of Independent Director for a period of 5 consecutive years, effective May 27, 2026. Result PDF